Gravity Analytica

Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

EYEN 11.07.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-12

Name of Upcoming Event:Investor Conference Call

Full Press Release SEC Filings Our EYEN Tweets

About Gravity Analytica

Recent Filings

Company to host an investor conference call and webcast at 4:30pm EDT

NEW YORK,Nov. 07, 2024(GLOBE NEWSWIRE) --Eyenovia, Inc.(NASDAQ: EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that the Company will release financial results for the third quarter endedSeptember 30, 2024onTuesday, November 12^th, 2024, after the markets close. Following the release,Eyenoviamanagement will host a conference call and webcast at4:30 p.m. ETto review the financial and operating results.

Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and reference Conference ID# 13748714.

To access the Call meTM feature, which avoids having to wait for an operator, clickhere.

A live webcast of the conference call will also be availablehereand on the investor relations page of the Company's corporate website atwww.eyenovia.com.

After the live webcast, the event will be archived on Eyenovia’s website for one year.

About Eyenovia, Inc.

Eyenovia, Inc.(NASDAQ: EYEN) is an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine to produce better treatment options and outcomes for patients and providers. The company’s pre-NDA candidate, MicroPine, is being developed for pediatric progressive myopia, a global epidemic impacting hundreds of millions of children worldwide and representing a multi-billion-dollar addressable market. The company’s current commercial portfolio includes clobetasol propionate ophthalmic suspension, 0.05%, for post-surgical pain and inflammation, and Mydcombi® for mydriasis.Eyenoviahas also secured licensing and development agreements for additional multi-billion-dollar indications where the Optejet may be advantageous, including dry eye. For more information, visitEyenovia.com.

For more information, visitEyenovia.com.

The Eyenovia Corporate Information slide deck may be found atir.eyenovia.com/events-and-presentations.

Eyenovia Contact:Eyenovia, Inc.Andrew JonesChief Financial Officerajones@eyenovia.com

Eyenovia Investor Contact:Eric RibnerLifeSci Advisors, LLCeric@lifesciadvisors.com(646) 751-4363

Eyenovia Media Contact:Eyenovia, Inc.Norbert LoweVice President, Commercial Operationsnlowe@eyenovia.com

Source: Eyenovia, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com